Medication-related osteonecrosis of the jaw: Prosthodontic considerations

Jpn Dent Sci Rev. 2022 Nov:58:9-12. doi: 10.1016/j.jdsr.2021.11.005. Epub 2021 Dec 18.

Abstract

Medication-related osteonecrosis of the jaw (MRONJ) can be triggered by several antiresorptive and antiangiogenic medications, including bisphosphonates (BRONJ), denosumab (DRONJ), and other agents used to treat osteoporosis and metastatic bone cancer. Prosthodontists and surgeons continue to face new challenges because of this condition. Despite the current evidence showing that extensive surgical intervention and laser surgery have the highest healing rates, surgical reconstruction is not always possible for large jaw defects requiring prosthetic reconstruction. Moreover, surgical treatment may not be an option in some patients because of other medical conditions. In these patients, MRONJ may develop into a chronic disease with limited resolution and they may seek prosthetic rehabilitation for aesthetic and functional reasons. Therefore, prosthetic intervention may be necessary for some patients with MRONJ even in the absence of a surgical defect. Denture trauma has been reported to be a risk factor for MRONJ, and few reports have discussed the prosthodontic considerations needed for patients with this condition. The aim of this review is to highlight the prosthodontic considerations that would decrease the risk of triggering MRONJ in susceptible patients.

Keywords: Antiresorptive agents; Bisphosphonates; Denosumab; Medication-related osteonecrosis of the jaw; Prosthodontic considerations.

Publication types

  • Review